Ixaka is a cell and gene therapy company focused on the natural power of the body to cure disease. Founded in 2015, it is headquartered in London (UK) with subsidiaries and laboratories in France and Spain.

Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease, and by directly modifying cells within the body to improve their therapeutic action.

Ixaka’s technologies – concentrated multi-cell therapies and nanoparticle therapeutics – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.